Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Patients in Clinical Cancer Trials: Understanding, Motivation and Hope
Uppsala universitet.ORCID iD: 0000-0001-6011-6740
2015 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

The overall aim of this thesis was to study participants' understanding of clinical cancer trials,and their motivation for participation. Of particular interest was the question of whether thepatients hoped for a cure resulting from the trial. The thesis was based on four studies andused three methods: interviews, a questionnaire, and empirical bioethics. The results of Study Iindicated that the participants in phase 1 trials understood most of the information provided, butwere unaware of both the very small potential for treatment benefit, and the risk of harm. Patientsin phase 3 trials had a good understanding of the trial, except regarding side effects and their rightto withdraw. Some found it hard to ask questions and felt they needed more information (StudyIII). The participants in phase 1 trials were strongly motivated by the generally unrealistic hopefor therapeutic benefit (Study I). When the chances of a cure are minuscule, as for participantswith end-stage cancer in phase 1 trials, hope can play an important, positive role and offermeaning to one’s remaining life. However, hope for an unrealistic outcome could also deprivepatients of an opportunity to spend their remaining lives, as they would otherwise choose(Study II). The participants in phase 3 trials indicated that their motivation for participationwas multifaceted; the most common motivations included hope of therapeutic benefit, altruism,access to extra clinical examinations or better care, and a wish to repay society for the helpthey had received (Study III). After stratifying and analysing the motivation data by gender,age, education and previous experience of trial participation, males and those aged ≥65 yearswere significantly more motivated to participate out of a desire to reciprocate the help theyhad received, either because of a sense of duty or because their families or friends consideredthat they should attend (Study IV). In conclusion, the informed consent process seems to workrelatively well, with good results within most subgroups. However, patients with end-stagecancer who are participating in phase 1 trials are a vulnerable group as they have very littlepotential for treatment benefit coupled with a tangible risk of harm.

Place, publisher, year, edition, pages
Uppsala: Uppsala universitet, 2015. , p. 79
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 1112
Keywords [en]
Cancer, Adults, Clinical trials, Phase 1 trials, Phase 3 trials, Patient information, Patient education, Informed consent, Hope
National Category
Nursing
Identifiers
URN: urn:nbn:se:esh:diva-7090Libris ID: 18030969ISBN: 978-91-554-9268-7 (print)OAI: oai:DiVA.org:esh-7090DiVA, id: diva2:1261795
Public defence
2015-08-28, BMC, A1:107a, Husargatan 3, Uppsala, 09:15 (Swedish)
Opponent
Supervisors
Available from: 2018-11-08 Created: 2018-11-08 Last updated: 2018-11-08Bibliographically approved
List of papers
1. "I Have a Lot of Pills in My Bag, You Know": Institutional Norms in the Provision of Hope in Phase I Clinical Cancer Trials.
Open this publication in new window or tab >>"I Have a Lot of Pills in My Bag, You Know": Institutional Norms in the Provision of Hope in Phase I Clinical Cancer Trials.
2017 (English)In: Journal of oncology practice, ISSN 1935-469X, Vol. 13, no 10, p. 679-682Article in journal, Editorial material (Refereed) Published
National Category
Nursing
Identifiers
urn:nbn:se:esh:diva-6989 (URN)10.1200/JOP.2017.021832 (DOI)28837376 (PubMedID)
Note

I avhandlingen Patients in Clinical Cancer TrialsUnderstanding, Motivation and Hope:

Godskesen, T., Hansson, M.G. & Kihlbom, U. (2014). ‘I have a lot of pills in my bag, you know”. Institutional norms in the provision of hope in phase 1 clinical cancer trials. (In manuscript).

Available from: 2018-10-23 Created: 2018-10-23 Last updated: 2019-01-07Bibliographically approved
2. Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation
Open this publication in new window or tab >>Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation
Show others...
2013 (English)In: Supportive Care in Cancer, ISSN 0941-4355, E-ISSN 1433-7339, Vol. 21, no 11, p. 3137-3142Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: In cancer, phase 1 clinical trials on new drugs mostly involve patients with advanced disease that is unresponsive to standard therapy. The purpose of this study was to explore the difficult ethical problems related to patient information and motives for participation in such trials.

METHOD: A descriptive and explorative qualitative design was used. Fourteen cancer patients from three different phase 1 trials in end-stage cancer were interviewed. The interviews were analysed using qualitative content analysis.

RESULTS: The patients expressed unrealistic expectations of therapeutic benefit and inadequate understanding of the trials' purpose, so-called therapeutic misconception. However, they reported a positive attitude towards participation. Thus, the patients valued the close and unique medical and psychological attention they received by participating. Participation also made them feel unique and notable.

CONCLUSIONS: Patients with end-stage cancer participating in phase 1 clinical trials are unaware of the very small potential for treatment benefit and the risk of harm. Trial participation may offer hope and social-emotional support and a strategy for coping with the emotional stress associated with advanced cancer and may, consequently, improve emotional well-being.

Keywords
Cancer, Clinical trials, Ethics, Sweden
National Category
Cancer and Oncology Medical Ethics
Identifiers
urn:nbn:se:esh:diva-6971 (URN)10.1007/s00520-013-1891-7 (DOI)23864288 (PubMedID)
Available from: 2018-10-05 Created: 2018-10-05 Last updated: 2018-11-08Bibliographically approved
3. Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials.
Open this publication in new window or tab >>Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials.
Show others...
2015 (English)In: European Journal of Cancer Care, ISSN 0961-5423, E-ISSN 1365-2354, Vol. 24, no 1, p. 133-41Article in journal (Refereed) Published
Abstract [en]

It is necessary to carry out randomised clinical cancer trials (RCTs) in order to evaluate new, potentially useful treatments for future cancer patients. Participation in clinical trials plays an important role in determining whether a new treatment is the best therapy or not. Therefore, it is important to understand on what basis patients decide to participate in clinical trials and to investigate the implications of this understanding for optimising the information process related to study participation. The aims of this study were to (1) describe motives associated with participation in RCTs, (2) assess if patients comprehend the information related to trial enrolment, and (3) describe patient experiences of trial participation. Questionnaires were sent to 96 cancer patients participating in one of nine ongoing clinical phase 3 trials at the Department of Oncology, Uppsala University Hospital in Sweden. Eighty-eight patients completed the questionnaire (response rate 92%); 95% of these were patients in adjuvant therapy and 5% participated in clinical trials on palliative care. Two main reasons for participation were identified: personal hope for a cure and altruism. Patients show adequate understanding of the information provided to them in the consent process and participation entails high patient satisfaction.

Keywords
Cancer, Clinical trials
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:esh:diva-6970 (URN)10.1111/ecc.12184 (DOI)24467443 (PubMedID)
Note

Available from: 2018-10-05 Created: 2018-10-05 Last updated: 2018-11-08Bibliographically approved
4. Differences in trial knowledge and motives for participation among cancer patients in phase 3 clinical trials.
Open this publication in new window or tab >>Differences in trial knowledge and motives for participation among cancer patients in phase 3 clinical trials.
Show others...
2016 (English)In: European Journal of Cancer Care, ISSN 0961-5423, E-ISSN 1365-2354, Vol. 25, no 3, p. 516-23Article in journal (Refereed) Published
Abstract [en]

While participants in clinical oncology trials are essential for the advancement of cancer therapies, factors decisive for patient participation have been described but need further investigation, particularly in the case of phase 3 studies. The aim of this study was to investigate differences in trial knowledge and motives for participation in phase 3 clinical cancer trials in relation to gender, age, education levels and former trial experience. The results of a questionnaire returned from 88 of 96 patients (92%) were analysed using the Mann-Whitney U-test. There were small, barely relevant differences in trial knowledge among patients when stratified by gender, age or education. Participants with former trial experience were less aware about the right to withdraw. Male participants and those aged ≥65 years were significantly more motivated by a feeling of duty, or by the opinions of close ones. Men seem more motivated than women by external factors. With the awareness that elderly and single male participants might be a vulnerable group and participants with former trial experience are less likely to be sufficiently informed, the information consent process should focus more on these patients. We conclude that the informed consent process seems to work well, with good results within most subgroups.

Keywords
Adults, Cancer, Clinical trials, Patient education, Patient information, Phase 3 trials
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:esh:diva-6969 (URN)10.1111/ecc.12319 (DOI)25904313 (PubMedID)
Available from: 2018-10-05 Created: 2018-10-05 Last updated: 2018-11-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

LIBRISFULLTEXT

Search in DiVA

By author/editor
Godskesen, Tove
Nursing

Search outside of DiVA

GoogleGoogle Scholar

isbn
urn-nbn

Altmetric score

isbn
urn-nbn
Total: 50 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf